Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and filgotinib (Jyseleca), have been approved for treatment of ulcerative colitis with several other JAK inhibitors in late-stage clinical trials for inflammatory bowel disease (IBD). Despite their impressive efficacy, the risk of adverse...

Full description

Saved in:
Bibliographic Details
Main Authors: Vipul Yadav (Author), Aileen House (Author), Silvia Matiz (Author), Laura E. McCoubrey (Author), Kimberly A. Bettano (Author), Leena Bhave (Author), Meiyao Wang (Author), Peter Fan (Author), Siqun Zhou (Author), Janice D. Woodhouse (Author), Eirini Poimenidou (Author), Liu Dou (Author), Abdul W. Basit (Author), Lily Y. Moy (Author), Robert Saklatvala (Author), Laxminarayan G. Hegde (Author), Hongshi Yu (Author)
Format: Book
Published: MDPI AG, 2022-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items